Across TCGA pan-cancer cohorts, LYPLA2P1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LYPLA2P1 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LYPLA2P1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LYPLA2P1 expression acts as an unfavorable survival marker.

LUSC are the cancer types where LYPLA2P1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.136	0.758	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: LYPLA2P1 tumor-vs-normal RNA expression · all LYPLA2P1 data types